BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 31920662)

  • 1. Effectiveness of Subcutaneous Tumor Necrosis Factor Inhibitors in Patients With Ankylosing Spondylitis: A Real-World Prospective Observational Cohort Study in China.
    Ji X; Wang Y; Hu Z; Ma Y; Man S; Li K; Wang Y; Zhu J; Zhang J; Huang F
    Front Pharmacol; 2019; 10():1476. PubMed ID: 31920662
    [No Abstract]   [Full Text] [Related]  

  • 2. Continuous Improvement of Physical Functioning in Ankylosing Spondylitis Patients by Tumor Necrosis Factor Inhibitors: Three-Year Followup and Predictors.
    van Weely SF; Kneepkens EL; Nurmohamed MT; Dekker J; van der Horst-Bruinsma IE
    Arthritis Care Res (Hoboken); 2016 Oct; 68(10):1522-9. PubMed ID: 26881893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor Necrosis Factor Inhibitor Discontinuation in Patients with Ankylosing Spondylitis: An Observational Study From the US-Based Corrona Registry.
    Mease PJ; van der Heijde D; Karki C; Liu M; Park Y; Greenberg JD
    Rheumatol Ther; 2018 Dec; 5(2):537-550. PubMed ID: 30353387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Effect of Tumor Necrosis Factor-Alpha Inhibitors on Uveitis in Patients with Ankylosing Spondylitis.
    Lee S; Park YJ; Lee JY
    J Korean Med Sci; 2019 Nov; 34(42):e278. PubMed ID: 31674159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physical Function and Spinal Mobility Remain Stable Despite Radiographic Spinal Progression in Patients with Ankylosing Spondylitis Treated with TNF-α Inhibitors for Up to 10 Years.
    Poddubnyy D; Fedorova A; Listing J; Haibel H; Baraliakos X; Braun J; Sieper J
    J Rheumatol; 2016 Dec; 43(12):2142-2148. PubMed ID: 27803139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Relapse of ankylosing spondylitis and its predictors after withdrawal of tumor necrosis factor-α inhibitors: a 52-week follow-up study].
    Tang C; Chen F; Zheng S; Wu L; Chen S; Zhu J; Li J
    Nan Fang Yi Ke Da Xue Xue Bao; 2021 May; 41(5):633-639. PubMed ID: 34134948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the comorbidity burden in patients with ankylosing spondylitis treated with tumour necrosis factor inhibitors using a large administrative claims data set.
    Walsh JA; Song X; Kim G; Park Y
    J Pharm Health Serv Res; 2018 Jun; 9(2):115-121. PubMed ID: 29861786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of extra-articular manifestations on tumor necrosis factor-α inhibitor treatment duration in patients with ankylosing spondylitis: nationwide data from the Korean College of Rheumatology BIOlogics (KOBIO) registry.
    Kim Y; Park S; Kim HS
    Clin Rheumatol; 2018 Dec; 37(12):3275-3284. PubMed ID: 30251059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of tapering tumor necrosis factor inhibitor on the achievement of inactive disease in patients with axial spondyloarthritis: a nationwide cohort study.
    Park JW; Kim HA; Shin K; Park YB; Kim TH; Song YW; Lee EY
    Arthritis Res Ther; 2019 Jul; 21(1):163. PubMed ID: 31272498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort.
    Molnar C; Scherer A; Baraliakos X; de Hooge M; Micheroli R; Exer P; Kissling RO; Tamborrini G; Wildi LM; Nissen MJ; Zufferey P; Bernhard J; Weber U; Landewé RBM; van der Heijde D; Ciurea A;
    Ann Rheum Dis; 2018 Jan; 77(1):63-69. PubMed ID: 28939631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to Tumor Necrosis Factor Inhibition in Male and Female Patients with Ankylosing Spondylitis: Data from a Swiss Cohort.
    Hebeisen M; Neuenschwander R; Scherer A; Exer P; Weber U; Tamborrini G; Micheroli R; Wildi LM; Zufferey P; Nissen MJ; Villiger PM; Bernhard J; Finckh A; van der Horst-Bruinsma IE; Sieper J; Landewé R; van der Heijde D; Ciurea A;
    J Rheumatol; 2018 Apr; 45(4):506-512. PubMed ID: 29449504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-life experience with switching TNF-α inhibitors in ankylosing spondylitis.
    Gulyas K; Bodnar N; Nagy Z; Szamosi S; Horvath A; Vancsa A; Vegh E; Szabo Z; Szucs G; Szekanecz Z; Szanto S
    Eur J Health Econ; 2014 May; 15 Suppl 1():S93-100. PubMed ID: 24832840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinimetric evaluation of the bath ankylosing spondylitis metrology index in a controlled trial of pamidronate therapy.
    Jauregui E; Conner-Spady B; Russell AS; Maksymowych WP
    J Rheumatol; 2004 Dec; 31(12):2422-8. PubMed ID: 15570645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ankylosing Spondylitis Response to TNF Inhibition Is Gender Specific: A 6-Year Cohort Study.
    Murray C; Fearon C; Dockery M; Moran D; Heffernan E; Fitzgerald O; Veale DJ; Harty L
    Ir Med J; 2018 Oct; 111(9):820. PubMed ID: 30556668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Efficacy of Advanced Therapies in the Treatment of Radiographic Axial Spondyloarthritis or Ankylosing Spondylitis as Evaluated by the ASDAS Low Disease Activity Criteria.
    Baraliakos X; Saffore CD; Collins EB; Parikh B; Ye X; Walsh JA
    Rheumatol Ther; 2024 Jun; ():. PubMed ID: 38858318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose Reduction of Tumor Necrosis Factor Inhibitor and its Effect on Medical Costs for Patients with Ankylosing Spondylitis.
    Koo BS; Lim YC; Lee MY; Jeon JY; Yoo HJ; Oh IS; Shin JY; Kim TH
    Rheumatol Ther; 2021 Mar; 8(1):347-359. PubMed ID: 33420967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Treatment With TNF-Alpha Inhibitors Improves Bone Mineral Density But Not Vertebral Fracture Progression in Ankylosing Spondylitis.
    Beek KJ; Rusman T; van der Weijden MAC; Lems WF; van Denderen JC; Konsta M; Visman I; Nurmohamed MT; van der Horst-Bruinsma IE
    J Bone Miner Res; 2019 Jun; 34(6):1041-1048. PubMed ID: 30690799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumour necrosis factor inhibitors slow radiographic progression in patients with ankylosing spondylitis: 18-year real-world evidence.
    Koo BS; Oh JS; Park SY; Shin JH; Ahn GY; Lee S; Joo KB; Kim TH
    Ann Rheum Dis; 2020 Oct; 79(10):1327-1332. PubMed ID: 32660979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment pattern, satisfaction, and productivity loss of patients with ankylosing spondylitis treated with tumor necrosis factor inhibitors in Korea: A multicenter cross-sectional observational study.
    Lee SH; Kim YG; Lee SG; Lee SH; Kim YJ; Jeon JY; Jo JY; Yoo HJ; Lee J; Kim TH
    Int J Rheum Dis; 2022 May; 25(5):523-531. PubMed ID: 35187866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting Probability of Response to Tumor Necrosis Factor Inhibitors for Individual Patients With Ankylosing Spondylitis.
    Wang R; Dasgupta A; Ward MM
    JAMA Netw Open; 2022 Mar; 5(3):e222312. PubMed ID: 35289857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.